Determination of in vitro antimicrobial susceptibility for Lefamulin (Pleuromutilin) for Ureaplasma Spp. and Mycoplasma hominis

Spiller-Boulter, Oliver, Paukner, Susanne, Boostrom, Ian, Sands, Kirsty, Portal, Edward A. R. and Spiller, Owen B. ORCID: https://orcid.org/0000-0002-9117-6911 2021. Determination of in vitro antimicrobial susceptibility for Lefamulin (Pleuromutilin) for Ureaplasma Spp. and Mycoplasma hominis. Antibiotics 10 (11) , 1370. 10.3390/antibiotics10111370

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (487kB) | Preview

Abstract

Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 Ureaplasma parvum, 25 Ureaplasma urealyticum, and 40 Mycoplasma hominis). All Mycoplasma hominis isolates possessed lefamulin MICs of ≤0.25 mg/L after 48 h (MIC50/90 of 0.06/0.12 mg/L), despite an inherent resistance to macrolides; while Ureaplasma isolates had MICs of ≤2 mg/L after 24 h (MIC50/90 of 0.25/1 mg/L), despite inherent resistance to clindamycin. Two U. urealyticum isolates with additional A2058G mutations of 23S rRNA, and one U. parvum isolate with a R66Q67 deletion (all of which had a combined resistance to macrolides and clindamycin) only showed a 2-fold increase in lefamulin MIC (1–2 mg/L) relative to macrolide-susceptible strains. Lefamulin could be an effective alternative antimicrobial for treating Ureaplasma spp. and Mycoplasma hominis infections irrespective of intrinsic or acquired resistance to macrolides, lincosamides, and ketolides. Based on this potent in vitro activity and the known good, rapid, and homogenous tissue penetration of female and male urogenital tissues and glands, further exploration of clinical efficacy of lefamulin for the treatment of Mycoplasma and Ureaplasma urogenital infections is warranted.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Advanced Research Computing @ Cardiff (ARCCA) Medicine
Publisher:	MDPI
ISSN:	2079-6382
Date of First Compliant Deposit:	16 November 2021
Date of Acceptance:	3 November 2021
Last Modified:	12 Jun 2024 12:18
URI:	https://orca.cardiff.ac.uk/id/eprint/145546

Actions (repository staff only)

Edit Item